REPROMEDA and BlueGnome (Brno, Czech Republic and Cambridge, UK) are pleased to announce that REPROMEDA has achieved ISO 15189 accreditation for use of BlueGnome’s 24sure platform for their laboratories in Brno, Czech Republic. REPROMEDA was founded in 1999 as a facility for reproductive medicine and assisted reproduction and was the first facility in Central and […]
Seegene introduces the first real time multiplex quantification test for Human Papilloma Virus (HPV)
Gaithersburg, Maryland and SEOUL, Korea, – Seegene Inc., (096530.KQ), a leading developer of multiplex molecular diagnostic technologies and tests, today announced the development and commercialization of the first molecular assay for the detection, genotyping and quantification of nineteen high-risk and nine low-risk genotypes of the Human Papilloma virus (HPV). Seegene’s breakthrough new test, QuantPlex(TM) HPV28 […]
HILDEN, Germany, and GERMANTOWN, Maryland, USA, – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today unveiled an advanced initiative to enter the field of next-generation sequencing (NGS) that aims to establish these technologies as routine processes used in new areas such as clinical research and molecular diagnostics. QIAGEN is in the advanced stages of […]
SAN DIEGO, — Trovagene, Inc. (Nasdaq: TROV), a developer of trans-renal molecular diagnostics, announced that Russell Investments has added Trovagene to the Russell Microcap Index based on Russell Investments annual reconstitution of its family of U.S. indexes finalized after the close of the U.S. markets on June 22, 2012. “We are pleased to be included […]
BREA, CALIF. — Beckman Coulter, Inc., the leader in prostate cancer diagnostics, announces Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for the Prostate Health Index (phi), a simple, non-invasive blood test that is 2.5 times more specific in detecting prostate cancer1 than PSA (prostate-specific antigen) in patients with PSA values in […]
Agilent Technologies Inc. (NYSE: A) today announced that its acquisition of cancer diagnostics company Dako has been completed. Agilent, which paid $2.2 billion in cash for Dako (on a debt-free basis), expects the acquisition to help strengthen Agilent’s position in life sciences, with a focus on product development to help in the fight against cancer. […]
LEXINGTON, MA – Predictive Biosciences today announced the introduction of next generation sequencing (NGS) into the company’s CertNDx™ bladder cancer tests. The company has developed a new, highly sensitive non-invasive urine-based assay that uses NGS to analyze FGFR3 mutations for bladder cancer detection, which demonstrated a significant improvement in sensitivity over the qPCR method currently […]
Austin, Texas – Asuragen, Inc. announced today that it has granted BD (Becton, Dickinson and Company), a global medical technology company, non-exclusive worldwide rights to incorporate Armored RNA® technology into its in vitro molecular diagnostics products. Under the terms of the Agreement, Asuragen will develop and supply reagents for BD Diagnostics in Asuragen’s cGMP manufacturing […]
BEDFORD, Mass. and SAN DIEGO, Calif., — Hologic, Inc. (Hologic) (NASDAQ: HOLX) and Gen-Probe Incorporated (Gen-Probe) (NASDAQ: GPRO) today announced that, in connection with Hologic’s proposed acquisition of Gen-Probe, the initial 30-day waiting period required under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired without a request for additional information from the Federal […]
Niel,– Multiplicom, a molecular diagnostics company specializing in innovative molecular genetics tests based on massive parallel sequencing, has received CE/IVD mark accreditation for its first-in-class BRCA MASTR Dx test. The test identifies mutations in the coding regions of the BRCA 1&2 genes in individuals with increased risk for breast, ovarian and/or related cancers. The test […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
